Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...

GLP-1 medications, such as Ozempic and Wegovy, are injected into the fatty layer beneath the skin to manage blood sugar and aid in weight management. The recommended injection sites include the ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

The GLP-1 medicine Wegovy is available as a shot or a pill. Which one is better for you? Compare them here. You’ve likely heard buzz (and seen commercials) about GLP-1 drugs for weight management, ...

Mon, December 8, 2025 at 2:21 PM UTC Abbott's medical device segment grew 14.8% to $5.45 billion. The cardiovascular portfolio drove results, with TriClip for tricuspid valve repair gaining Japan ...

Common GLP-1s include semaglutides like Ozempic and Wegovy, and tirzepatides like Zepbound and Mounjaro. These drugs work by mimicking a natural hormone to regulate appetite, blood sugar, and feelings ...

Experts describe the development of oral GLP-1 medication as a “pivotal” improvement in the accessibility and adherence to obesity drugs. As of February 2026, only Wegovy and Rybelsus are available in ...

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...

Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% ...